SNDX Syndax Pharmaceuticals Inc
Price (delayed)
$12.97
Market cap
$1.12B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.72
Enterprise value
$1.31B
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab,
Highlights
The revenue has grown by 48% from the previous quarter
The gross profit is up by 43% since the previous quarter
The net income has plunged by 52% YoY and by 7% from the previous quarter
SNDX's equity is down by 48% YoY and by 21% QoQ
Key stats
What are the main financial stats of SNDX
Market
Valuations
Earnings
Shares outstanding
86.02M
Market cap
$1.12B
Enterprise value
$1.31B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.84
Price to sales (P/S)
46.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
55.2
Revenue
$23.68M
Gross profit
$22.85M
Operating income
-$339.67M
Net income
-$318.76M
EBIT
-$313.83M
EBITDA
-$312.83M
Free cash flow
-$274.9M
Per share
Balance sheet
Liquidity
EPS
-$3.72
EPS diluted
-$3.72
Free cash flow per share
-$3.21
Book value per share
$3.38
Revenue per share
$0.28
TBVPS
$8.47
Total assets
$724.82M
Total liabilities
$436.69M
Debt
$345.74M
Equity
$288.12M
Working capital
$499.51M
Debt to equity
1.2
Current ratio
5.82
Quick ratio
5.74
Net debt/EBITDA
-0.61
Margins
Efficiency
Dividend
EBITDA margin
-1,321.1%
Gross margin
96.5%
Net margin
-1,346.1%
Operating margin
-1,434.4%
Return on assets
-58.7%
Return on equity
-80.7%
Return on invested capital
-71.5%
Return on capital employed
-50.5%
Return on sales
-1,325.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SNDX stock price
How has the Syndax Pharmaceuticals stock price performed over time
Intraday
7.99%
1 week
-1.22%
1 month
-17.07%
1 year
-44.31%
YTD
-1.89%
QTD
5.58%
Financial performance
How have Syndax Pharmaceuticals's revenue and profit performed over time
Revenue
$23.68M
Gross profit
$22.85M
Operating income
-$339.67M
Net income
-$318.76M
Gross margin
96.5%
Net margin
-1,346.1%
The net income has plunged by 52% YoY and by 7% from the previous quarter
The revenue has grown by 48% from the previous quarter
The operating income has contracted by 48% YoY and by 6% from the previous quarter
The gross profit is up by 43% since the previous quarter
Growth
What is Syndax Pharmaceuticals's growth rate over time
Valuation
What is Syndax Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.84
P/S
46.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
55.2
The EPS has declined by 25% year-on-year and by 2.2% since the previous quarter
SNDX's equity is down by 48% YoY and by 21% QoQ
SNDX's price to book (P/B) is 13% lower than its last 4 quarters average of 4.1
The revenue has grown by 48% from the previous quarter
Efficiency
How efficient is Syndax Pharmaceuticals business performance
The company's return on equity has shrunk by 68% YoY and by 26% QoQ
Syndax Pharmaceuticals's return on assets has decreased by 33% YoY
The return on sales is up by 29% since the previous quarter
The return on invested capital rose by 28% since the previous quarter but it has declined by 3.6% year-on-year
Dividends
What is SNDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SNDX.
Financial health
How did Syndax Pharmaceuticals financials performed over time
The total assets is 66% more than the total liabilities
The total assets has soared by 70% from the previous quarter and by 18% YoY
SNDX's current ratio is down by 42% year-on-year and by 17% since the previous quarter
SNDX's debt is 20% more than its equity
SNDX's equity is down by 48% YoY and by 21% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.